Resminostat granted Orphan Drug status against Hodgkin's

Submitted by Ross Bonander Tue 09/27/2011

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

According to a press release issued by the company, 4SC (in the business of the discovery and development of oncology products) announced that the United States FDA has granted Orphan Drug status to the firm's oncology compound resminostat for the treatment of Hodgkin's lymphoma.

This is the drug's second such indication. Only recently, the FDA granted Orphan Drug status to resminostat for the treatment of hepatocellular carcinoma (HCC).

Resminostat, an oral pan-histone-deacetylase inhibitor (HDAC, or "H-dack"), is also being explored against colorectal cancer.

The Hodgkin's lymphoma indication comes on the heels of the results of the phase II SAPHIRE study, which considered resminostat as a possible third-line therapeutic intervention in patients with relapsed/refractory Hodgkin's lymphoma. The results, as reported by the company, showed an overall response rate of 33.3 percent, and over half the patients showing a "clinical benefit" from resminostat.

There is currently no consensus on a third-line therapy for relapsed or refractory Hodgkin's lymphoma.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.